AGENUS INC. (NASDAQ:AGEN) Files An 8-K Other Events
Item 8.01 Other Events.
Agenus Inc. announced today that the first patient has been dosed
in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody
INCAGN1949. The trial is being conducted by, and in collaboration
with, Incyte Corporation. The open-label, dose-escalation portion
of the trial will evaluate the safety and tolerability of
INCAGN1949 in patients with advanced or metastatic solid tumors
and determine its pharmacologically active and/or maximum
tolerated dose. Part 2 of the trial is planned to evaluate the
recommended dose of INCAGN1949 in multiple tumor types.
INCAGN1949 is an agonist antibody targeting OX40, otherwise known
as CD134 or TNFRSF4. OX40 is a co-stimulatory receptor found on
activated T cells. OX40 engagement has a two-pronged effect; it
can stimulate proliferation of activated T cells that may promote
tumor killing and inhibit the activity of regulatory T cells that
mediate immune suppression. INCAGN1949 was discovered during an
earlier collaboration with Ludwig Cancer Research. This antibody
is being co-developed with Incyte Corporation.
The full text of the press release issued in connection with the
announcement is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit |
| 99.1 | Press Release dated November 30, 2016. |
About AGENUS INC. (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. AGENUS INC. (NASDAQ:AGEN) Recent Trading Information
AGENUS INC. (NASDAQ:AGEN) closed its last trading session 00.00 at 4.35 with 1,273,508 shares trading hands.
